The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global
threat to public health. Vancomycin remains one of the first-line drugs for the treatment of …

The treatment of bacterial infections is increasingly complicated by the ability of bacteria to
develop resistance to antimicrobial agents. Antimicrobial agents are often categorized …

The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and
heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past …

Staphylococcus aureus is capable of becoming resistant to all classes of antibiotics clinically
available and resistance can develop through de novo mutations in chromosomal genes or …

Significant advances have been made in recent years in our understanding of how
methicillin resistance is acquired by Staphylococcus aureus. Integration of a staphylococcal …

Vancomycin is usually reserved for treatment of serious infections, including those caused
by multidrug-resistant Staphylococcus aureus. A clinical isolate of S. aureus with high-level …

Vancomycin has been the most reliable therapeutic agent against infections caused by
meticillin-resistant Staphylococcus aureus (MRSA). However, in 1996 the first MRSA to …

Gram‐positive bacteria possess a permeable cell wall that usually does not restrict the
penetration of antimicrobials. However, resistance due to restricted penetration can occur …

We have previously shown that a thickened cell wall is responsible for the vancomycin
resistance of vancomycin-resistant Staphylococcus aureus (VRSA)(equivalent to …

Infections caused by multidrug-resistant Gram-positive bacteria represent a major public
health burden, not just in terms of morbidity and mortality, but also in terms of increased …